InMed files CTA to start second Phase 1 INM-755 clinical trial
Category: #health  By Nikita Chaurasia  Date: 2020-03-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

InMed files CTA to start second Phase 1 INM-755 clinical trial

InMed Pharmaceuticals Inc., a leading biopharmaceutical company which develops medications targeting diseases with unmet needs, has reportedly announced the filing of CTA (Clinical Trial Application) in the Netherlands to commence a second Phase 1 trial in humans to assess INM-755 in healthy subjects.

755-102-HV is a Phase 1 study which is double-blind, randomized, as well as vehicle-controlled. It is designed to assess the tolerability and safety of INM-755 cream being applied on a daily basis on epidermal wounds in healthy volunteers. Overall, two strengths of the INM-755 cream would be assessed over a 14-day treatment period in 8 adult subjects.

Alexandra Mancini, Senior VP, Clinical and Regulatory Affairs, InMed, stated that the second Phase 1 trial is another essential step towards the efficacy trials of INM-755.

Mancini further stated that the review of the CTA application would continue as usual in spite of the restrictions in place in the Netherlands due to the COVID-19 epidemic. The enrollment would begin soon as the CTA is approved, and the restrictions are lifted.

About InMed Pharmaceuticals:

InMed Pharmaceuticals is a biopharmaceutical company specializing in the discovery as well as development of new cannabinoid-based therapeutics for illnesses with significant unmet medical need. The firm is focused on the creation of new therapeutic substitutes to patients that might benefit from medicines that are cannabinoid based.

The firm takes on a highly scientific approach for designing and developing medicines, which further aids in unlocking the full potential of cannabinoid pharmaceuticals.

About INM-755:

INM-755 is CBN cream which is proposed as a topical therapy for the treatment of EB (epidermolysis bullosa) and possibly other dermatological diseases. The preclinical data signifies that INM-755 might help alleviate hallmark EB symptoms like pain and inflammation and possibly reinstate the integrity of the skin in a subgroup of EB simplex patients.

Source credit: https://finance.yahoo.com/news/inmed-submits-clinical-trial-application-113000611.html

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
By Nikita Chaurasia

Israel-based leading provider of advanced solutions for cybersecurity, IoT (Internet of Things) and e-Government sectors Supercom has reportedly signed a supply agreement to deliver its PureSecurity EM (Electronic Monitoring) product suite in Wiscons...

FAA grants approval for mass air shipment of Pfizer’s COVID-19 vaccine
FAA grants approval for mass air shipment of Pfizer’s COVID-19 vaccine
By Nikita Chaurasia

Chicago-headquartered airline company United Airlines Inc. has reportedly started operating charter flights for the distribution of Pfizer Inc.’s COVID-19 vaccine after receiving approval from the Federal Aviation Authority (FAA). For the reco...

Twitter releases plans to relaunch verification program in early 2021
Twitter releases plans to relaunch verification program in early 2021
By Nikita Chaurasia

Twitter Inc. has reportedly planned to relaunch the user verification program as well as a new public application process by 2021. According to reliable sources, the move will allow the American social networking company to address the confusion rega...